Trial watch: dietary interventions for cancer therapy

Sarah Lévesque, Jonathan G Pol, Gladys Ferrere, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Sarah Lévesque, Jonathan G Pol, Gladys Ferrere, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer

Abstract

Dietary interventions have a profound impact on whole body metabolism, including oncometabolism (the metabolic features allowing cancer cells to proliferate) and immunometabolism (the catabolic and anabolic reactions that regulate immune responses). Recent preclinical studies demonstrated that multiple dietary changes can improve anticancer immunosurveillance of chemo-, radio- and immunotherapy. These findings have fostered the design of clinical trials evaluating the capacity of dietary interventions to synergize with treatment and hence limit tumor progression. Here, we discuss the scientific rationale for harnessing dietary interventions to improve the efficacy of anticancer therapy and present up-to-date information on clinical trials currently investigating this possibility.

Keywords: Alternate-day fasting; caloric restriction mimetics; chemotherapy; fasting-mimicking diet; immune checkpoint blockers; ketone bodies.

References

    1. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet Lond Engl. 2016;387(10026):1377–1396. doi:10.1016/S0140-6736(16)30054-X.
    1. Hossain P, Kawar B, El Nahas M.. Obesity and diabetes in the developing world–a growing challenge. N Engl J Med. 2007;356(3):213–215. doi:10.1056/NEJMp068177.
    1. Bianchini F, Kaaks R, Vainio H.. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565–574. doi:10.1016/S1470-2045(02)00849-5.
    1. Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, Iqbal R, Kumar R, Wentzel-Viljoen E, Rosengren A, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. The Lancet. 2017;390(10107):2050–2062. doi:10.1016/S0140-6736(17)32252-3.
    1. Myles IA. Fast food fever: reviewing the impacts of the Western diet on immunity. Nutr J. 2014;13:61. doi:10.1186/1475-2891-13-61.
    1. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364(25):2392–2404. doi:10.1056/NEJMoa1014296.
    1. Kroemer G, López-Otín C, Madeo F, de Cabo R. Carbotoxicity-noxious effects of carbohydrates. Cell. 2018;175(3):605–614. doi:10.1016/j.cell.2018.07.044.
    1. Lock K, Pomerleau J, Causer L, Altmann DR, McKee M. The global burden of disease attributable to low consumption of fruit and vegetables: implications for the global strategy on diet. Bull World Health Organ. 2005;83:100–108.
    1. Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, Whelton PK. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first national health and nutrition examination survey epidemiologic follow-up study. Am J Clin Nutr. 2002;76(1):93–99. doi:10.1093/ajcn/76.1.93.
    1. World Health Organization WHO Global nutrition policy review 2016–2017. 2018. [accessed February15, 2019].
    1. Pellizzon M. Choice of laboratory animal diet influences intestinal health. Lab Anim. 2016;45:238–239. doi:10.1038/laban.1014.
    1. Warden CH, Fisler JS. Comparisons of diets used in animal models of high-fat feeding. Cell Metab. 2008;7(4):277. doi:10.1016/j.cmet.2008.03.014.
    1. Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. Am J Gastroenterol. 2013;108(5):748–758. doi:10.1038/ajg.2013.77.
    1. Deschasaux M, Huybrechts I, Murphy N, Julia C, Hercberg S, Srour B, Kesse-Guyot E, Latino-Martel P, Biessy C, Casagrande C, et al. Nutritional quality of food as represented by the FSAm-NPS nutrient profiling system underlying the nutri-score label and cancer risk in Europe: results from the EPIC prospective cohort study. PLoS Med. 2018;15(9):e1002651. doi:10.1371/journal.pmed.1002651.
    1. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet Lond Engl. 2002;360(9336):861–868. doi:10.1016/S0140-6736(02)09958-0.
    1. Jansen MCJF, Bueno-de-Mesquita HB, Feskens EJM, Streppel MT, Kok FJ, Kromhout D. Quantity and variety of fruit and vegetable consumption and cancer risk. Nutr Cancer. 2004;48(2):142–148. doi:10.1207/s15327914nc4802_3.
    1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group . Body fatness and cancer–viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602.
    1. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–591. doi:10.1038/nrc1408.
    1. Font-Burgada J, Sun B, Karin M. Obesity and cancer: the oil that feeds the flame. Cell Metab. 2016;23(1):48–62. doi:10.1016/j.cmet.2015.12.015.
    1. Merletti F, Galassi C, Spadea T. The socioeconomic determinants of cancer. Environ Health Glob Access Sci Source. 2011;10(Suppl 1):S7. doi:10.1186/1476-069X-10-S1-S7.
    1. Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep. 2012;2(2):257–269. doi:10.1016/j.celrep.2012.06.017.
    1. Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng C-W, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell. 2016;30(1):136–146. doi:10.1016/j.ccell.2016.06.005.
    1. Di Biase S, Longo VD. Fasting-induced differential stress sensitization in cancer treatment. Mol Cell Oncol. 2016;3(3):e1117701. doi:10.1080/23723556.2015.1117701.
    1. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell. 2016;30(1):147–160. doi:10.1016/j.ccell.2016.05.016.
    1. Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, Conti PS, Chen TC, Longo VD. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7(9):e44603. doi:10.1371/journal.pone.0044603.
    1. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev. 2014;33(1):217–229. doi:10.1007/s10555-014-9495-3.
    1. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, Pistoia V, Wei M, Hwang S, Merlino A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27. doi:10.1126/scitranslmed.3003293.
    1. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10(9):671–684. doi:10.1038/nrd3504.
    1. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12(11):829–846. doi:10.1038/nrd4145.
    1. O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553–565. doi:10.1038/nri.2016.70.
    1. Gruenbacher G, Thurnher M. Mevalonate metabolism governs cancer immune surveillance. Oncoimmunology. 2017;6(10):e1342917. doi:10.1080/2162402X.2017.1342917.
    1. Bantug GR, Galluzzi L, Kroemer G, Hess C. The spectrum of T cell metabolism in health and disease. Nat Rev Immunol. 2018;18(1):19–34. doi:10.1038/nri.2017.99.
    1. Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, Sanchez MD, Dean MJ, Rodriguez PC, Ochoa AC. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology. 2017;6(10):e1344804. doi:10.1080/2162402X.2017.1344804.
    1. Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570–586. doi:10.1016/j.cell.2017.04.004.
    1. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology. 2013;2(6):e24612. doi:10.4161/onci.24612.
    1. Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(1):e27297. doi:10.4161/onci.27297.
    1. Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell. 2008;134(5):703–707. doi:10.1016/j.cell.2008.08.021.
    1. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–482. doi:10.1016/j.ccr.2008.05.005.
    1. Starkova J, Hermanova I, Hlozkova K, Hararova A, Trka J. altered metabolism of leukemic cells: new therapeutic opportunity. Int Rev Cell Mol Biol. 2018;336:93–147. doi:10.1016/bs.ircmb.2017.07.012.
    1. Costa ASH, Frezza C. Metabolic reprogramming and oncogenesis: one hallmark, many organelles. Int Rev Cell Mol Biol. 2017;332:213–231. doi:10.1016/bs.ircmb.2017.01.001.
    1. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006.
    1. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497(7451):633–637. doi:10.1038/nature12138.
    1. Fais S. Cannibalism: a way to feed on metastatic tumors. Cancer Lett. 2007;258(2):155–164. doi:10.1016/j.canlet.2007.09.014.
    1. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi:10.1038/oncsis.2015.49.
    1. Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, Marchetti S, et al. Low-protein diet induces IRE1α-dependent anticancer immunosurveillance. Cell Metab. 2018;27(4):828–842.e7. doi:10.1016/j.cmet.2018.02.009.
    1. Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, van Den Broek NJF, Mackay GM, Labuschagne CF, Gay D, Kruiswijk F, et al. Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 2017;544(7650):372–376. doi:10.1038/nature22056.
    1. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67(8):789–796. doi:10.1038/ejcn.2013.116.
    1. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25(2):262–284. doi:10.1016/j.cmet.2016.12.022.
    1. Klement RJ, Champ CE, Otto C, Kämmerer U. Anti-tumor effects of ketogenic diets in mice: a meta-analysis. PLoS One. 2016;11(5):e0155050. doi:10.1371/journal.pone.0155050.
    1. Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499–503. doi:10.1038/s41586-018-0343-4.
    1. Crudden C, Shibano T, Song D, Suleymanova N, Girnita A, Girnita L. Blurring boundaries: receptor tyrosine kinases as functional G protein-coupled receptors. Int Rev Cell Mol Biol. 2018;339:1–40. doi:10.1016/bs.ircmb.2018.02.006.
    1. Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nat Rev Cardiol. 2019;16(1):33–55. doi:10.1038/s41569-018-0074-0.
    1. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA. 2008;105(24):8215–8220. doi:10.1073/pnas.0708100105.
    1. Raffaghello L, Longo V. Metabolic alterations at the crossroad of aging and oncogenesis. Int Rev Cell Mol Biol. 2017;332:1–42. doi:10.1016/bs.ircmb.2017.01.003.
    1. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, Hwang D, Cohen P, Bianchi G, Longo VD. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70(4):1564–1572. doi:10.1158/0008-5472.CAN-09-3228.
    1. Buono R, Longo VD. Starvation, stress resistance, and cancer. Trends Endocrinol Metab. 2018;29(4):271–280. doi:10.1016/j.tem.2018.01.008.
    1. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012.
    1. Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G. Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. Oncoimmunology. 2018;7(10):e1484980. doi:10.1080/2162402X.2018.1484980.
    1. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi:10.1038/nrc3380.
    1. Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6(12):e1386829. doi:10.1080/2162402X.2017.1386829.
    1. Galluzzi L, Kroemer G. An epigenetic modifier triggers therapeutic immune responses against breast cancer. Oncoimmunology. 2017;6(5):e1313376. doi:10.1080/2162402X.2017.1313376.
    1. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573–1577. doi:10.1126/science.1208347.
    1. Galluzzi L, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cecconi F, Choi AM, Chu CT, Codogno P, Colombo MI, et al. Molecular definitions of autophagy and related processes. Embo J. 2017;36(13):1811–1836. doi:10.15252/embj.201796697.
    1. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, et al. Autophagy in malignant transformation and cancer progression. Embo J. 2015;34(7):856–880. doi:10.15252/embj.201490784.
    1. Burger T, Molnár L, Schmelzer M, Tóvari E, Szabó A, Paál M, Királyfalvi L. Changes in T lymphocyte subgroups and their effect in chronic B-lymphoid leukemia. Orv Hetil. 1988;129:2189–2193.
    1. Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15(6):382–396. doi:10.1038/s41571-018-0006-2.
    1. Derosa L, Routy B, Kroemer G, Zitvogel L. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. Oncoimmunology. 2018;7(6):e1434468. doi:10.1080/2162402X.2018.1434468.
    1. Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, et al. Dietary protein restriction reprograms tumor-associated macrophages and enhances immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(24):6383–6395. doi:10.1158/1078-0432.CCR-18-0980.
    1. Soldati L, Di Renzo L, Jirillo E, Ascierto PA, Marincola FM, De Lorenzo A. The influence of diet on anti-cancer immune responsiveness. J Transl Med. 2018:16. doi:10.1186/s12967-018-1448-0.
    1. Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, et al. Trial watch: immune checkpoint blockers for cancer therapy. Oncoimmunology. 2017;6(11):e1373237. doi:10.1080/2162402X.2017.1373237.
    1. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, López-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:459. doi:10.1126/scitranslmed.aat7807.
    1. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–151. doi:10.1038/s41591-018-0221-5.
    1. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: a case series report. Aging. 2009;1(12):988–1007. doi:10.18632/aging.100114.
    1. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng C-W, Brandhorst S, Cohen P, Wei M, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16. doi:10.1186/s12885-016-2370-6.
    1. Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, Kunz B, Brückner B, Sehouli J, Michalsen A. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18(1):476. doi:10.1186/s12885-018-4353-2.
    1. de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, Sánchez-Margalet V. Breast cancer immunology and immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1–53. doi:10.1016/bs.ircmb.2016.09.008.
    1. de Groot S, Vreeswijk MPG, Welters MJP, Gravesteijn G, Boei JJWA, Jochems A, Houtsma D, Putter H, van der Hoeven JJM, Nortier JWR, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15:652. doi:10.1186/s12885-015-1663-5.
    1. Cohen CW, Fontaine KR, Arend RC, Soleymani T, Gower BA. Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: a randomized, controlled trial. Nutrients. 2018;10:9. doi:10.3390/nu10091187.
    1. Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, Shah RB. Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the veterans affairs Pittsburgh healthcare system. Nutr Metab. 2016;13:52. doi:10.1186/s12986-016-0113-y.
    1. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–1852. doi:10.3892/ijo.2014.2382.
    1. Lapeyre-Prost A, Terme M, Pernot S, Pointet A-L, Voron T, Tartour E, Taieb J. Immunomodulatory activity of VEGF in cancer. Int Rev Cell Mol Biol. 2017;330:295–342. doi:10.1016/bs.ircmb.2016.09.007.
    1. Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, et al. Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab. Oncoimmunology. 2018;7(11):e1457598. doi:10.1080/2162402X.2018.1457598.
    1. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2:6. doi:10.3978/j.issn.2305-5839.2014.06.01.
    1. Cha J-H, Yang W-H, Xia W, Wei Y, Chan L-C, Lim S-O, Li C-W, Kim T, Chang -S-S, Lee -H-H, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606–620.e7. doi:10.1016/j.molcel.2018.07.030.
    1. Qin G, Lian J, Huang L, Zhao Q, Liu S, Zhang Z, Chen X, Yue D, Li L, Li F, et al. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology. 2018;7(7):e1442167. doi:10.1080/2162402X.2018.1442167.
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
    1. Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17:854–855. doi:10.1038/nrd.2018.210.
    1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa1001294.
    1. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019;8(1):e1486953. doi:10.1080/2162402X.2018.1486953.
    1. Wang A, Luan HH, Medzhitov R. An evolutionary perspective on immunometabolism. Science. 2019;363:6423. doi:10.1126/science.aar3932.
    1. Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, Kreutz M. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol. 2017:8. doi:10.3389/fimmu.2017.00248.
    1. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Ortega VA, Hernández-Lizoain JL, Baixauli J, Becerril S, Rotellar F, Valentí V, et al. IL-32α-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology. 2017;6(7):e1328338. doi:10.1080/2162402X.2017.1328338.
    1. Zilberter T, Zilberter Y. Ketogenic ratio determines metabolic effects of macronutrients and prevents interpretive bias. Front Nutr. 2018:5. doi:10.3389/fnut.2018.00075.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren